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Abstract 
Rhenium complexes with the antibiotic ciprofloxacin have been prepared to be studied 
as models of technetium radiopharmaceuticals. With this aim, the new rhenium 
complexes 1 {[ReO(Cpf)2]Cl}, 2 {[ReO(CpfH)2]Cl3} and 3 {fac-[Re(CO)3(H2O)(Cpf)]} 
with ciprofloxacin (CpfH = ciprofloxacin; Cpf = conjugated base of ciprofloxacin) have 
been synthesised and characterised by elemental analyses, IR, NMR (
1
H, 
19
F and 
13
C 
CP-MAS) spectroscopy, as well as MS measurements. All spectroscopic data are 
consistent with the coordination of ciprofloxacin in all these complexes through the 
carbonyl and the carboxylate oxygen atoms with the formation of a six member chelate 
ring. 
The study of a Tc-ciprofloxacin solution by ESI-MS reveals the presence of 
[TcO(Cpf)2]
+
 cations, which agrees with the hypothesis that complexes 1 and 2 can be 
seen as model rhenium complexes of this radiopharmaceutical. 
Antimicrobial and DNA Gyrase inhibition studies performed with complexes 2 and 3 
have shown a very similar behaviour between complex 2 and the free antibiotic, 
whereas complex 3 exhibit a lower antimicrobial activity. 
Based on a joint analysis of the data reported in the literature and the chemical and 
biological results obtained in this study, a tentative proposal to explain some aspects of 
the behaviour of Tc-ciprofloxacin radiopharmaceutical has been made 
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1. Introduction 
 
Molecular imaging techniques are very powerful tools in medicine because they 
allow visualising biochemical process in living organisms by non-invasive methods. 
Images can be obtained either by measuring the absorption of externally applied 
radiation (NMR, CT), or the radiation escaping from the body. In the second case, a 
diagnostic radiopharmaceutical, a molecule that contains an unstable radionuclide which 
decomposes with the emission of gamma rays, should be administered to the patient. 
The radionuclide Tc-99m is widely used in radiopharmacy for this purpose due to its 
availability through the 
99
Mo/
99m
Tc generator and its near ideal nuclear properties (half-
life of 6h and γ-ray energy of 141 keV).1,2 The high penetration ability of photons allows 
gamma radiation to escape from the body and to be detected externally. The analysis of 
the in vivo behaviour of the radiopharmaceutical makes it possible to differentiate 
normal from abnormal anatomical structures or biochemical functions. Current research 
with technetium radiopharmaceuticals is focused on the development of bioactive 
substances with specific biological properties linked to the technetium metal.
3,4
 
Despite significant advances in medicine, infections remain a major health 
problem and a cause of patient mortality worldwide. The use of specific 
radiopharmaceuticals for infection imaging is an attracting approach, as it is a sensitive 
methodology that allows a site of an occult infection to be located earlier.
5,6
 
Radiolabelled leucocytes is currently one of the most commonly used 
radiopharmaceuticals in hospitals for this purpose, but radiolabelled antimicrobial 
peptides and radiolabelled antibiotics are also being studied as potential alternatives.
5,6
 
Ciprofloxacin is one of the most common and widely used antibacterial agents (Scheme 
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1). It is a synthetic antibiotic belonging to fluoroquinolone group with a broad-spectrum 
bacteria-localising capability.
7,8
 Fluoroquinolones suppress the growth of bacteria by 
inhibiting the activity of DNA gyrase, an essential bacterial enzyme that relieves strain 
while double-stranded DNA is being unwound.
7,9,10
 Technetium-99m labelled 
ciprofloxacin (
99m
Tc-ciprofloxacin or Infecton) was first introduced in the 1990s and has 
been extensively studied as an infection-specific radiopharmaceutical.
5,11-16
 However, 
the global analysis of numerous published studies (including clinical trials) shows 
contradictory data about the specificity of 
99m
Tc-ciprofloxacin. Thus, different authors 
have claimed that this radiopharmaceutical can not properly differentiate a bacterial 
infection from an aseptic inflammation.
5,15,16
 One of the main problems to elucidate the 
behaviour of this radiopharmaceutical is that, although it has been studied for two 
decades, there is no information about its molecular structure. This situation is due to 
attempts to prepare a model rhenium complex of 
99m
Tc-ciprofloxacin have been 
unsuccessful,
17
 and the structural analysis of the Tc-99m complex is not possible as it is 
prepared at very low concentration (10
-7
-10
-8
 M).
1,2
 If a model rhenium complex was 
available, the influence of metal coordination in the antibacterial properties of 
ciprofloxacin could be analyzed, and this is a key point to understand how this 
compound works as diagnostic radiopharmaceutical. We must realise that, in a first 
approximation, it seems very strange that the coordination of ciprofloxacin to the metal 
does not significantly alter its antibacterial properties. Particularly, if we take into 
account that the atoms that probably interact with the metal (4-oxo carbonyl and 
carboxylate oxygen atoms) are the same that have been proposed to interact with DNA 
gyrase.
7,9
 In contrast to this view, other authors have proposed that metal atoms can be 
involved in the interaction between ciprofloxacin and DNA-gyrase ,
7, 18-20
 which could 
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explain the antibacterial properties of Tc-ciprofloxacin. 
(Scheme 1) 
An interesting aspect is that the metal complexes of quinolones have been 
extensively studied. Thus, complexes with different metals such as, Mg,
20, 21
 Al,
22
 V,
23
 
Mn,
21, 24
 Fe,
24, 25
 Co,
21, 24, 26
 Ni,
24, 26
 Cu,
26, 27
 Zn,
21, 26, 28
 Y,
29
 Zr,
29
 Mo,
24
 Ag,
30
 Cd,
21, 26
 
Pt,
31
 U
32
 and Eu
33
 have been reported, and there is even a review of these metal 
complexes.
19
 As mentioned above, the most common coordination mode of 
ciprofloxacin is through the oxygen atoms of the 4-oxo carbonyl and the carboxylate 
groups, forming a chelating ring of six atoms. Only a few examples have been reported, 
in which the coordination through the nitrogen atoms of the piperazine ring of 
ciprofloxacin is shown or proposed.
30, 31
 
As far as we know, only one rhenium complex with a derivative of ciprofloxacin 
has been reported,
34
 but in this case the studied ligand is obtained by a coupling reaction 
between a tridentate chelator and the piperazinyl nitrogen of ciprofloxacin. This 
structural modification changes the coordination ability of the molecule and the metal is 
coordinated to the tridentate chelator, while the carbonyl and the carboxylate groups of 
ciprofloxacin remain free. The objective of this modification is to obtain a new 
molecule that preserves the capability of the antibiotic to bind bacteria, and that can also 
form stable bonds with technetium. Following the same approach, three works with Tc-
99m have been published that contain other structural modifications of ciprofloxacin.
35-
37
 In recent years, and in some cases in conjunction with structural modifications of 
ciprofloxacin, the substitution of the hypothetical Tc(V) fragment {TcO}
3+
 by the 
technetium tricarbonyl {fac-Tc(CO)3} has been explored in order to improve the 
potential radiopharmaceutical properties of technetium complexes with ciprofloxacin.
34, 
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37, 38
 The use of technetium carbonyls in radiopharmacy has been greatly stimulated after 
the development of fac-[
99m
Tc(H2O)3(CO)3]
+
 because this cation contains three labile 
water molecules that can be easily substituted by other ligands yielding a wide range of 
stable complexes useful for radiopharmaceutical purposes.
3, 39, 40
 
The aim of this paper is to prepare rhenium complexes with ciprofloxacin that 
can be useful as model compounds of 
99m
Tc-ciprofloxacin to study their antibacterial 
properties, and to provide valuable data for understanding the behaviour of this 
radiopharmaceutical. This work will be complemented with a study in which the Re(V) 
will be replaced by the rhenium tricarbonyl fragment. This approach will allow us to 
compare the interaction of the two different fragments with ciprofloxacin and to supply 
comparative data for their antibacterial properties, which can shed some light on the 
understanding of the radiopharmaceutical properties of technetium ciprofloxacin 
derivatives. Part of this work was previously communicated.
41
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2. Materials and methods 
 
2.1. Starting materials and methods 
 
All reactions were performed under nitrogen using standard Schlenk tube 
techniques. Infrared spectra were recorded with a Perkin-Elmer 2000 FT spectrometer. 
The NMR spectra were recorded in the Servei de Ressonància Magnètica Nuclear de la 
Universitat Autònoma de Barcelona on Bruker DPX-250, DPX-360 and AV400 
instruments. Microanalyses were performed by the Servei d’Anàlisi Química del 
Departament de Química de la Universitat Autònoma de Barcelona. Mass spectra and 
exact mass measurements were respectively obtained on an Esquire 3000 with 
electrospray ionization and an ion trap Bruker Daltonics and on a Bruker microTOFQ 
with electrospray ionization Apollo by Servei d’Anàlisi Química del Departament de 
Química de la Universitat Autònoma de Barcelona. 
Rhenium complexes [ReO2(py)4]Cl·2H2O,
42
 [ReO2(py)4][PF6],
43
 
[NBu4][ReOCl4]
44
 and [Re(CO)5(O3SCF3)]
45
 were prepared by published procedures. 
The preparation method for 
99
Tc-ciprofloxacin was identical to that previously 
reported
46
 but the technetium concentration was increased to 1.4 nmol/mL (the mass 
amount of technetium was calculated using algorithms derived from the radioactive 
equilibriums in the generator
47
) to improve performance in ESI-MS. This was achieved 
by radioactive decay of solutions with high activity. The concentration of technetium 
under these conditions was 10-100 times higher than in the no-carrier added conditions. 
The HPLC-MS (ESI) system used for this study consisted of a Liquid Chromatograph 
(Agillent 1100 HPLC) equipped with a RP C18 column (XTerra MS C18 Waters; 50 × 
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2.1 mm × 3.5 μm) eluted at a flow rate of 0.3 mL/min. The column was eluted with 
gradient mixtures of acetonitrile (0’: 5 %, 6’: 5 %, 12’: 60 %, 13’: 60 %, 15’: 5 %, 22’: 
5 %) and formic acid 0.25 %. The column eluate was directed to the spectrometer 
(Esquire 3000 with electrospray ionization and an ion trap Bruker Daltonics). Although 
the study was performed in the positive and negative mode, only a significant signal in 
the positive mode with the appropriate isotopic pattern was observed in the positive 
mode at 774.9 m/z (Rt = 3.2, 10.4 min). 
 
 
2.2. Chemical synthesis 
 
2.2.1 Synthesis of 1 
 
The precursor [ReO2(py)4]Cl·2H2O (130 mg, 0.21 mmol) was dissolved in MeOH (5 
mL) and added to a suspension of ciprofloxacin (150 mg, 0.45 mmol) in the same 
solvent (45 mL). The mixture was heated at the reflux temperature for 2 h. The obtained 
dark brown solution was concentrated under vacuum to 5 mL and the resulting solution 
was cooled to 4 ºC to crystallize the complex. The solid was washed with cold MeOH 
and Et2O to give a brown solid 1 (120 mg). IR (ATR, cm
-1
, relevant peaks): 1730(m) 
(CO, free ciprofloxacin), 1630(s), 1454(s) (CO, OCO), 896(s) (Re=O). 
1
H-NMR (DMSO-
d6, δ): 8.82 (s, 1H, H-2), 8.02 (d, J = 12.8 Hz, 1H, H-5), 7.68 (b, 1H, H-8), 3.81 (b, 1H, 
H-9), 3.64 (b, 4H, H-11), 3.50 (b, 4H, H-12), 1.30 (m, 4H, H-10). 
19
F{
1
H}-NMR 
(DMSO-d6, δ): -123.6. 
13
C CP-MAS: 174.5 (C-4), 165.7 (carboxylate), 154.8, 152.4 (C-
6), 148.6 (C-2), 144.9 (C-7), 139.3 (C-4a), 117.0 (C-8a), 109.7 (C-5), 106.3 (C-3), 105.0 
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(C-8), 46.2 (C-11/ C-12), 36.1 (C-9), 8.2 (C-10). HRMS (ESI) (positive mode, m/z): 
Calcd. for C34H34F2N6O7Re (M-Cl
-
) 863.2011, found 863.1977. 
 
2.2.2 Synthesis of 2 
 
A solution of [NBu4][ReOCl4] (70 mg, 0.12 mmol) in dry methanol (10 mL) was added 
dropwise to a suspension of ciprofloxacin (86 mg, 0.26 mmol) in the same solvent (10 
mL) at 0°C. Next, the mixture was stirred for 1 h at the same temperature. The resulting 
dark-brown solution was reduced to 5 mL under vacuum and cooled to -30 ºC for 12 h. 
The dark brown precipitated was filtered and washed with 5 mL of dry acetone, 5 mL of 
dry Et2O and dried under vacuum to obtain the complex 2 (63 mg, 53 %). IR (ATR, cm
-
1
, relevant peaks): 1626(s), 1451(s) (CO, OCO),
 
899(m) (Re=O). 
1
H-NMR (MeOD, δ): 
8.82 (s, 1H, H-2), 8.02 (d, J = 12.8 Hz, 1H, H-5), 7.68 (b, 1H, H-8), 3.81 (b, 1H, H-9), 
3.64 (b, 4H, H-11), 3.50 (b, 4H, H-12), 1.30 (m, 4H: H-10).
19
F{
1
H}-NMR (MeOD, δ): -
123.6. 
13
C CP-MAS(δ): 175.4 (C-4), 167.9 (carboxilate), 153.6, 151.0 (C-6), 146.5 (C-
2), 143.9 (C-7), 139.2 (C-4a), 117.8 (C-8a), 112.2 (C-5), 106.9 (C-3), 104.8 (C-8), 44.6 
(C-11/ C-12), 36.8 (C-9), 8.5 (C-10). Anal. Calcd. for C34H36Cl3F2N6O7Re·H2O: C, 
41.28 H, 3.87 N, 8.50 %. Found: C, 41.08 H, 3.98 N, 8.32 %. HRMS (ESI) (positive 
mode, m/z): Calcd. for C34H34F2N6O7Re (M-3Cl
-
-2H
+
) 863.2011, found 863.2015. 
 
2.2.3 Synthesis of 3 
 
The complex Re(CO)5O3SCF3 (154 mg, 0.60 mmol) was dissolved in water (10 mL) 
and heated to reflux temperature for 1 h. Then, a water solution of ciprofloxacin (200 
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mg, 0.60 mmol) at pH = 3 was added and the heterogeneous mixture was heated to 
reflux temperature for 2 h with vigorous stirring. Next, the mixture was cooled in an ice 
bath and a suspension of a pale-yellow solid was formed. The solid was filtered and 
washed with 10 mL of cold water, 10 mL of methanol, 10 mL of Et2O and dried under 
vacuum to afford 3 (231 mg, 62%). IR (ATR, cm
-1
, relevant peaks): 2018(s), 1871(s) 
(CO), 1614(s), 1480(s) (CO, OCO). 
1
H-NMR (DMSO-d6, δ): 8.85 (m, 1H, H-2), 7.85 
(m, 1H, H-5), 7.45 (m, 1H, H-8), 3.35 (m, 9H, H-9/ H-11/ H-12), 1.20 (m, 4H, H-10). 
19
F{
1
H}-NMR (DMSO-d6, δ): -120.9. 
13
C CP-MAS: δ 198.3 (CO), 175.9 (C-4), 168 
(carboxylate), 148.6 (C-2, C-6, C-7), 138.9 (C-4a) 121.2 (C-8a), 111.5 (C-3/ C-5/ C-8), 
44.9 (C-11/ C-12), 36.8 (C-9), 8.1 (C-10). ESI MS (positive mode, m/z): 602.2 (M-
H2O+H
+
). Anal. Calcd. for C20H19FN3O7Re: C, 38.83 H, 3.10 N, 6.79 %. Found: C, 
38.44 H, 3.25 N, 6.67 %. 
 
 
2.3. Antimicrobial susceptibility test 
 
Antimicrobial activities of the complexes 2 and 3 were evaluated using a 
methodology similar as previously described.
48, 49
 Briefly, 24h cultures of tested 
microorganisms: Pseudomonas aeruginosa (ATCC 27853), Escherichia coli (ATCC 
25922), Staphylococcus aureus (ATCC 25923) and Enterococcus faecalis (ATCC 
29212) were stirred with NaCl 0.9 % solution and adapted to the concentration of 2x 10
8
 
cfu/ml. A sterile cotton swab was dipped into bacterial suspension and streaked over 
Mueller-Hinton agar plates (Oxoid). Filter paper discs Ø 6 mm (Whatman) were 
drenched with test complexes (5 µg of product). Plates were incubated at 37ºC for 18h. 
Acce
pted
 man
uscr
ipt
 11 
The diameters of inhibition zones were measured. Ciprofloxacin (5 µg; Oxoid) was used 
as reference substance. 
 
 
2.4. DNA gyrase cleavage assay 
 
The solutions of complexes were prepared as follow: compound 2 and 
ciprofloxacin hydrochloride (used as control) were dissolved in sterile MilliQ grade 
water. Complex 3 was dissolved in a small volume of DMSO and the solution was 
diluted with sterile MilliQ grade water to the desired assay concentrations (from 1 to 
250 µM). In all cases, the DMSO final concentration was less than 2.5 %. 
DNA gyrase cleavage assay was carried out following the recommendations of the 
manufacturer (Inspiralis). Briefly, 0.5 µl (1U) of DNA gyrase was incubated with 0.5 µg 
of supercoiled pBR322 in a reaction volume of 30µl at 37ºC for 1 hour in a 1X assay 
buffer (Inspiralis). Ciprofloxacin or the assay complexes (2, 3) were added at the desired 
concentrations (from 1 to 250 µM). Following, sodium dodecyl sulfate and proteinase K 
were added to final concentrations of 0.2 % and 0.1 mg/ml, respectively, and the 
incubation was continued for 30 min at 37 ºC. The reactions were stopped by adding 30 
µl Stop buffer (40 % sucrose, 100 mM Tris.HCl (pH 7.5), 100 mM EDTA, 0.5 µg/mL 
bromophenol blue), followed by extraction with 1 volume of chloroform/isoamyl 
alcohol (24:1). Then 20 µl of aqueous phase of each sample was analysed on 1% 
agarose gels in 1 % TAE (40 mM Tris-Acetate, 2 mM EDTA) and visualized after 
staining with ethidium bromide in a ChemiDoc XRS apparatus (Bio Rad Laboratories). 
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3. Results and discussion 
 
3.1. MS-ESI spectrum of 
99
Tc-Ciprofloxacin 
 
As has been stated in the introduction, is not possible to obtain structural information 
from very dilute solutions of Tc-99m compounds. However, in recent years has been 
demonstrated that it is possible to obtain MS-ESI spectra of solutions of technetium 
complexes, particularly if the technetium concentration is increased.
50, 51
 Using this 
approach, an aqueous solution of 
99
Tc-ciprofloxacin (prepared using previously reported 
method
46
) was analysed by MS-ESI spectrometry. It should be emphasized that the 
concentration of different species (free ciprofloxacin, tartrate, Cl
-
, Na
+
, Sn
2+
) in the 
analyzed solution is several orders of magnitude higher than the concentration of 
technetium, which represents a major drawback to detect the ionization of the 
technetium species. However, using an HPLC column previously to the injection it was 
possible to observe a peak in the positive mode (Figure 1) corresponding to the ion 
[TcO(Cpf)2]
+
 (Cpf = conjugate base of ciprofloxacin). Although, due to of the 
experimental conditions it can not be excluded the formation of other species, this 
stoichiometry is reasonable and agrees with the expected reactivity of ciprofloxacin 
because it is consistent with the formation of a bis-chelate complex as it is shown in 
Scheme 2. As mentioned in the introduction, the coordination of ciprofloxacin through 
the carbonyl and the carboxylate oxygen atoms with formation of a six members chelate 
ring is the most frequently observed in ciprofloxacin metal complexes.
19
 Regarding the 
metal, Tc(V) complexes are commonly obtained after the reaction between [TcO4]
-
 and 
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Sn
2+
, and mono-oxo [Tc
V
O]
3+
 complexes are formed if Tc(V) is coordinated to anionic 
ligands which contain carboxylate groups that can act as (O,O)-chelate ligands.
2, 52
 
(Figure 1) 
Therefore, the stoichiometry [TcO(Cpf)2]
+
 obtained from MS-ESI study with 
99
Tc-ciprofloxacin is consistent with a plausible structure for this complex, and it was 
chosen as a reference to prepare a model rhenium complex. 
(Scheme 2) 
 
3.2. Synthesis and characterisation of rhenium ciprofloxacin 
complexes 
 
3.2.1. Rhenium (V) complexes 
 
The first approach to prepare a [ReO(Cpf)2]
+
 complex was based on the substitution 
reaction of labile pyridine ligands in the trans-dioxo rhenium precursor trans-
[ReO2(py)4]
+
 by ciprofloxacin, as shown in Scheme 3. This reaction was studied using a 
wide range of experimental conditions, such as: different precursors ([ReO2(py)4]Cl, 
[ReO2(py)4][PF6]), solvents (acetone, ethanol, methanol), reaction times and 
temperatures. The hydrothermal reaction was also studied using similar reaction 
conditions to those reported in the preparation of some ciprofloxacin metal 
complexes.
19, 21, 28
 The worst results were obtained in those tests carried out in 
hydrothermal conditions, or in acetone as a reaction medium, which led to slightly 
coloured solutions and the recovery of ciprofloxacin as the main product. In contrast, 
reactions in methanol gave rise to dark brown solutions, and no significant quantities of 
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free ciprofloxacin were observed. Experiments in ethanol showed better results than in 
acetone, but appreciably lower than tests performed in methanol. Hence, after choosing 
methanol as the most appropriate reaction medium, the influence of temperature and 
reaction time was tested in this solvent, which showed that the best results are obtained 
if the reaction is performed at reflux temperature, and with a reaction time of nearly 2 
hours (if reaction time is considerably increased above this value, the product was 
contaminated by substantial amounts of free ciprofloxacin). The concentration of the 
methanol solution under reduced pressure and subsequent cooling at 4ºC led to the 
formation of a dark brown precipitate (1) that was characterised by the usual 
spectroscopic and spectrometric methods. 
(Scheme 3) 
The ESI-MS of a methanolic solution of 1 in the positive region shows a sole 
main signal with the characteristic isotopic pattern of ions that contain rhenium and the 
high-resolution mass spectrum (HRMS) evidence that this signal at 863.1977 (m/z) fully 
agrees with the stoichiometry [ReO(Cpf)2]
+
. 
The 
1
H NMR spectrum of 1 is very similar to the spectrum of free ciprofloxacin, 
although show some small changes that agree more with the coordination of 
ciprofloxacin through the oxygen atoms of carboxylate and carbonyl groups than with 
the coordination through the piperazine ring. Thus, no significant changes are observed 
in the methylene hydrogens of piperazine ring,
31
 whereas slight down field shifts are 
noticed in the H2, H5 and H8 hydrogen atoms of the quinolone ring.
53
 In order to obtain 
information about the binding mode of ciprofloxacin, the 
13
C spectrum is more useful 
because carbon atoms are directly linked to the heteroatoms susceptible of bonding to 
the metal. However, attempts to obtain a 
13
C NMR spectrum of 1 in solution were 
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unsuccessful because the solubility of this compound is low, which force too long 
acquisition times in order to observe the signals of atoms of quinolone ring. This long 
time involves some decomposition of 1, and a slight precipitate of free ciprofloxacin 
was observed in the NMR tube. Attempts to isolate a monocrystal of complex 1 for X-
ray analysis were unsuccessful for this same reason. This behaviour forced us to study 
this complex by solid-state NMR methods using cross-polarization and magic angle 
spinning experiments (CP-MAS). On comparing the 
13
C CP-MAS spectra of complex 1 
and ciprofloxacin, small changes in the 0-50 ppm region can be observed (Figure 2, 
numbering of carbon atoms is shown in Scheme 1), whereas the most relevant 
modifications are detected in the 160-180 ppm region. Thus, in free ciprofloxacin a sole 
signal is observed that has been assigned to the carboxylate and C4 carbon atoms.
22
 The 
coordination of the metal through the oxygen atoms of carbonyl and carboxylate groups 
exerts a strong influence on these carbon atoms directly bonded to these oxygen and 
these resonances are observed in the complex 1 as two different peaks. This assignment 
is consistent with the reported study with complex [Al(CpfH)3]Cl3 (CpfH = 
ciprofloxacin).
22
 
(Figure 2) 
The IR spectrum also suggests ciprofloxacin coordination through the oxygen 
atoms of carboxylate and carbonyl groups, in accordance with the NMR spectroscopy. 
Thus, two intense signals are observed at 1630 and 1454 cm
-1
, which have been 
assigned to the vibrations of carboxylate and ketone groups in previously reported 
ciprofloxacin metal complexes with the proposed coordination of ciprofloxacin.
19, 29, 54
 
The presence of an oxorhenium metal fragment in 1 is also consistent with this IR 
spectrum, since an intense band at 896 cm
-1
 is observed, which can be assigned to the 
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(Re=O) vibration.55 The contamination of 1 by small quantities of free ciprofloxacin 
was revealed by a signal of medium intensity observed at 1730 cm
-1
. This fact agrees 
with the results observed in the different synthetic assays and with the observed 
tendency of the solutions of 1 to decompose, yielding free ciprofloxacin. In order to 
obtain the complex 1 free of ciprofloxacin or another complex with a similar structure, a 
new synthetic method was designed, based on a substitution reaction with a rhenium 
precursor that can be performed at low temperature. Hence, the reaction between the 
very reactive rhenium precursor [ReOCl4]
-
 and ciprofloxacin leads to complex 2, as 
shown in Scheme 4. The ESI-MS of methanol solutions of 1 and 2 in the positive region 
are identical, and no significant differences are observed in the 
13
C CP-MAS spectra of 
both complexes. The main difference is observed in the intensity of signal at C11-C12 
atoms, which is more intense for complex 2 and it is slightly shifted. These data suggest 
that the structure of the two complexes should be very similar. However, the elemental 
analysis shows values significantly different for 2, which agree with the stoichiometry 
[ReO(CpfH)2]Cl3 for this compound. This result agrees with the above spectroscopic 
data and provides evidence that the structures of the two complexes are nearly identical 
but the secondary nitrogen atom of the piperazine ring is protonated in complex 2 or, in 
other words, the ciprofloxacin ligand is coordinated in its zwitterionic form. It is 
consistent with the synthetic method used to prepare this complex, since the [ReOCl4]
-
 
anion reacts vigorously with acidic hydrogen atoms to form hydrogen chloride. 
Therefore, we can suppose that the acid generated by the reaction with the carboxylic 
hydrogen atom is responsible for the protonation of the piperazine nitrogens. The 
absence of free ciprofloxacin in this complex is evidenced by the IR spectrum (no signal 
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is observed at 1730 cm
-1
), and this fact agrees with the idea that the reaction at a lower 
temperature minimises the presence of free ciprofloxacin in the final product. 
(Scheme 4) 
 
3.2.2. Rhenium (I) complex 
 
A rhenium carbonyl complex with ciprofloxacin was prepared by direct reaction 
between aqueous solutions of fac-[Re(H2O)3(CO)3]
+
 
56
 and ciprofloxacin, as shown in 
Scheme 5. The pH is a key factor in this process, because the complex fac-
[Re(H2O)3(CO)3]
+
 can undergo a deprotonation in water, leading to dimeric or trimeric 
species as [Re2(-OH)3(CO)6]
-
,
57
 so it is necessary to maintain this solution at pH 
neutral or slightly acidic. Furthermore, the acidic medium avoids contaminating the final 
product by free ciprofloxacin, since the solubility of ciprofloxacin in water is very low 
at neutral pH, but it is soluble at the pH of the reaction. Complex 3 was obtained as a 
yellow solid that showed very low solubility in most of the solvents, but it was possible 
to obtain the ESI-MS spectrum. It shows a peak at 602.2 (m/z) with the characteristic 
isotopic pattern of rhenium compounds that is assigned to the M+H
+
-H2O signal of 
complex 3. As in the previous rhenium ciprofloxacin complexes, the 
1
H NMR spectrum 
gives very little information but shows slight down field shifts of hydrogen atoms of the 
quinolone ring, which agrees with the coordination of ciprofloxacin through the oxygen 
atoms of carboxylate and carbonyl groups. This hypothesis agrees with the 
13
C CP-MAS 
spectrum of complex 3, which is very similar to the spectrum of 1 and 2 in the 160-180 
ppm region, showing two signals that are assigned to the carbon atoms directly bonded 
to the oxygen atoms linked to rhenium.
22
 The IR spectra also agrees with the proposed 
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coordination for ciprofloxacin, showing two intense signals at 1614 and 1480 cm
-1
, in 
concordance with the observed values for complexes 1-2, and with reported data for 
other complexes with this coordination.
19, 29, 54
 No signal was observed at 1730 cm
-1
, 
showing that this complex is free of contamination with ciprofloxacin and two intense 
peaks, assigned to the characteristic υ(CO) absorptions of the fac-{Re(CO)3} fragment, 
are shown at 2018 and 1871 cm
-1
. All these data agree with the structure proposed in 
Scheme 5 for complex 3, in which the ciprofloxacin coordination is identical to that of 
complexes 1-2, but in this case the metal fragment is fac-{Re(CO)3} instead of 
{ReO
3+
}. 
(Scheme 5) 
 
3.3. Antimicrobial activity 
 
Antimicrobial activities of the rhenium complexes 2 and 3 were evaluated using the agar 
disk-diffusion method against Gram-positive and Gram-negative bacteria, and the 
results are presented in Table 1. The low solubility of rhenium complexes forces 
dimethylsulfoxide to be used as solvent and, for that reason, the activity against this 
molecule is shown. The results reveal that the activity of rhenium complex 2 against all 
studied strains is nearly identical to that found for the ciprofloxacin, which is used as a 
reference compound. Alternatively, the activity of the rhenium complex 3 is slightly 
lower than the activity of the free ciprofloxacin. These results agree with previous 
reported data about the antimicrobial activity of quinolone metal complexes. Thus, in 
most of these studies, the reported antimicrobial activities are very similar to, or slightly 
lower than, those of free quinolones.
19, 23, 54, 58
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(Table 1) 
The fact that the rhenium metal complexes of ciprofloxacin exhibits 
antimicrobial activity can explain the properties of Tc-ciprofloxacin 
radiopharmaceutical, since the similarities between technetium and rhenium chemistry 
and between the radiuses of both elements are well known.
1
 In other words, if the 
coordination of the antibiotic to the metal does not significantly alter their antimicrobial 
properties, it could explain the high concentration of radionuclide in infected regions. 
Another interesting result, is to observe that the coordination of ciprofloxacin to the 
metal fragment fac-{Re(CO)3} has more influence on the antimicrobial activity than if it 
is coordinated to the {ReO
3+
} fragment. We will discuss this result further in the next 
section. 
 
3.4. Inhibition of DNA Gyrase  
 
As previously stated in the introduction, DNA Gyrase is a type II topoisomerase that 
relaxes supercoiled DNA and also introduces negative supercoils into the double 
stranded DNA in bacterial replication. The antibacterial properties of quinolones are due 
to their capability of acting as inhibitors of this enzyme.
7, 10, 59
 Different proposals have 
been made to understand the mechanism of Gyrase inhibition but the molecular details 
are unknown.
7, 9, 10, 59
 It should be mentioned that some authors support the idea that 
metal atoms are involved in the inhibitions mechanism of Gyrase by quinolones. For 
this reason, quinolones are also known as metallo-antibiotics,
60
 and different studies on 
Gyrase inhibition by quinolone metal complexes have been reported.
19, 58, 61, 62
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 Since in 
99m
Tc-ciprofloxacin radiopharmaceutical the ability to act as a diagnosis 
agent is a consequence of their antibiotic properties and the presence of the technetium 
radionuclide, we have performed a study of the Gyrase inhibition by the model rhenium 
ciprofloxacin complexes in order to obtain experimental data on the inhibition 
capabilities of the metal complexes. 
 The study of Escherichia coli topoisomerase II (named DNA Gyrase) inhibition 
by complexes 2 and 3 was performed by agarose gel electrophoresis using E coli DNA 
Gyrase cleavage assay kit (Inspiralis) and supercoiled pBR322 plasmid DNA (the study 
of 1 was omitted due to the contamination of this complex by free ciprofloxacin). The 
plasmid was incubated with a unit of DNA Gyrase in the presence of different 
concentrations (1 to 250 µM) of the free antibiotic (ciprofloxacin chlorhydrate) or the 
metal complexes 2 and 3, and following the manufacturer’s methodology. The results 
obtained in the assay control with ciprofloxacin chlorhydrate are shown in Figure 3. 
Thus, when Gyrase was added to the supercoiled DNA (lane 1), a series of topoisomers 
are formed due to the presence of various degrees of cleavage by the action of the 
enzyme (these topoisomers are less compacted and move at different speeds in agar) and 
the track is observed as a ladder. Lanes 2-7 show the influence of different 
concentrations of tested compounds on the activity of Gyrase. The top image 
corresponds to results obtained with ciprofloxacin chlorhydrate and show that, even at 
very low antibiotic concentrations, the intensity of the lower band assigned to 
supercoiled DNA increases, which is caused by the inhibitory action of the antibiotic. 
On comparing these results with data obtained for complex 2 (Figure 3, central image), 
we can observe a very similar behaviour between this compound and free ciprofloxacin, 
which points to a inhibition capacity of complex 2 very similar to that of the free 
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antibiotic. In contrast, the analysis of the results obtained with complex 3 (Figure 3, 
bottom image) shows that, although this complex also inhibits DNA Gyrase, the 
behaviour is slightly different than in the other two compounds. Thus, in this case a 
higher concentration of the tested compound is necessary ( 10 M) to minimise the 
formation of the different topoisomers that are observed as a ladder in the agar gel. 
Consequently, these results are consistent with the observed antimicrobial activity, and 
confirm that the antibacterial properties of complex 2 are nearly identical to those of the 
free ciprofloxacin, while complex 3 shows a slightly different behaviour. Hence, 
although this complex also shows antibacterial properties, exhibits a lower activity than 
free ciprofloxacin. 
(Figure 3) 
 On comparing the results obtained in the biological assays with complexes 2 and 
3 with the chemical behaviour observed with these compounds, we can tentatively 
suggest a plausible explanation for the radiopharmaceutical properties of the 
homologous technetium complexes. Thus, the fact that the antibacterial properties of 
complex 2 are nearly identical to those of free ciprofloxacin, together with the 
observation that complex 2 has a manifest tendency to decompose to free ciprofloxacin, 
suggest a probable dissociation of 
99m
Tc-ciprofloxacin during the interaction between 
the radiopharmaceutical and the bacteria. This hypothesis agrees with the observed 
labile properties of 
99m
Tc-ciprofloxacin
46
 and with the reported study on its 
accumulation in Staphylococcus aureus and Pseudomonas aeruginosa
63
 that showed 
that 
99m
Tc-ciprofloxacin was accumulated intracellularly in the ciprofloxacin-resistant 
strains. This result was associated with a possible dissociation of 
99m
Tc-ciprofloxacin 
after entering the cell.
63
 The labile character of O-donor complexes with Tc(V) as 
99m
Tc-
Acc
pted
 man
uscr
ipt
 22 
Gluconate,
64
 as well as the higher labile character of technetium complexes as regards 
their homologous rhenium complexes,
65
 also points in this direction. According to this 
hypothesis, the behaviour of 
99m
Tc-ciprofloxacin could be seen as similar to that of the 
radiopharmaceutical 
111
In-oxine, which is known to dissociate after entering the cell.
66
 
 
 
 
 
 
 
4. Conclusions 
 
Three new rhenium complexes with ciprofloxacin have been prepared, and in all cases 
the spectroscopic measurements agree with a coordination of the ciprofloxacin molecule 
to the metal thorough the carbonyl and the carboxylate oxygen atoms with formation of 
a six member chelate ring. These rhenium complexes can be used as model compounds 
of technetium radiopharmaceuticals. The MS analysis of 
99
Tc-ciprofloxacin is consistent 
with this hypothesis, since it shows the formation of homologous [MO(Cpf)2]
+
 (M = Tc, 
Re) ions with technetium and rhenium. 
The biological studies with rhenium ciprofloxacin complexes have shown that, when the 
antibiotic is coordinated to the {ReO}
3+
 fragment, the antibacterial activity is nearly 
identical to that of free ciprofloxacin, whereas if it is linked to the fac-{Re(CO)3} 
fragment it is significantly lower. From these results and previously reported data, we 
propose that the behaviour of Tc-ciprofloxacin radiopharmaceutical (Infecton) can be 
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associated with the dissociation of the labile [TcO(Cpf)2]
+
 complex after entering the 
cell. 
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Figure 3 
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Table 1 
 
Antimicrobial activities for complexes 2 and 3 measured by disk-diffusion method 
following the Clinical and Laboratory Standards Institute guidelines for ciprofloxacin: 
+(≤15mm); ++(16-20mm); +++(≥21mm) [49]. 
 
 
 
 
 
 
 
 
 
 Products 
Microorganisms CpfH 2 3 DMSO 
Staphylococcus aureus +++ +++ ++ - 
Enterococcus faecalis +++ +++ ++ - 
Escherichia coli +++ +++ +++ - 
Pseudomonas aeruginosa +++ +++ +++ - 
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FIGURE CAPTIONS 
 
Figure 1: ESI-MS spectrum (positive mode) of a 
99
Tc-ciprofloxacin aqueous solution 
 
Figure 2: 
13
C CP-MAS spectra of free ciprofloxacin (top) and complex 1 (bottom). 
 
Figure 3: Agarose gel electrophoresis of pBR322 plasmid DNA showing the effect of 
ciprofloxacin and metal complexes 2 and 3 on E. coli Gyrase cleavage assay. Lane L, 
Linear conformation; Lane SC, supercoiled pBR322; Lane 1, pBR322+Gyrase; Lane 2, 
pBR322 + Gyrase + 1 µM tested compound; Lane 3, pBR322 + Gyrase + 5 µM tested 
compound; Lane 4, pBR322 + Gyrase + 10 µM tested compound; Lane 5, pBR322 + 
Gyrase + 50 µM tested compound; Lane 6, pBR322 + Gyrase + 100 µM  tested 
compound; Lane 7, pBR322 + Gyrase + 250 µM tested compound. 
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GRAPHICAL ABSTRACT 
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